Keller Rohrback Files Suit Against Athira Pharma for Misrepresentations in IPO Registration Statement
A class action lawsuit has been filed against Athira Pharma (NASDAQ: ATHA) by Keller Rohrback and Longman Law, P.C. The case follows allegations of misrepresentation in Athira's IPO registration statement, particularly concerning CEO Dr. Leen Kawas. After Dr. Kawas was placed on temporary leave due to allegations of falsifying research results, Athira's stock plummeted nearly 40% from $18.24 to $11.15 per share, below the IPO price of $17.00. The lawsuit seeks remedies under the Securities Act of 1933 for affected shareholders.
- None.
- Filed a class action lawsuit against Athira Pharma over alleged misrepresentation in IPO registration.
- Stock price fell approximately 40% following news about CEO's alleged research misconduct.
Keller Rohrback and co-counsel Longman Law, P.C. filed a class action lawsuit against Athira Pharma, Inc. (“Athira”) (NASDAQ: ATHA), certain of its officers and directors, and the underwriters of the IPO of Athira common stock. The suit, entitled Timothy Slyne, et al. v. Athira Pharma, Inc., et al., was filed in the Western District of Washington on behalf of purchasers of ATHA common stock who either purchased shares in the September 2020 initial public offering (IPO) or on the open market that can be traced to the IPO. The lawsuit seeks remedies pursuant to the Securities Act of 1933.
The lawsuit alleges that Defendants misrepresented and omitted crucial truths regarding Athira Chief Executive Officer and President Dr. Leen Kawas in the Registration Statement for the IPO. Athira announced after close of trading on June 17, 2021 that the Athira Board placed Dr. Kawas on temporary leave in light of claims that she falsified research results in various academic papers. This news caused Athira’s stock to plunge approximately
Athira’s misrepresentations about its President and CEO and omission regarding the alleged research misconduct caused injury to all those who purchased Athira common stock pursuant or traceable to the IPO. If you purchased or acquired ATHA common stock pursuant to or traceable to the IPO, please contact Keller Rohrback’s securities team at investor@kellerrohrback.com or (800) 776-6044.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS A LEAD PLAINTIFF.
About Keller Rohrback L.L.P.
With offices in Seattle, Phoenix, New York, Oakland, Santa Barbara, and Missoula, Keller Rohrback serves as lead and co-lead counsel in class actions throughout the country. The firm has a track record for holding corporations accountable for wrongdoing and has achieved large settlements on behalf of its clients, including a
Attorney advertising. Prior results do not guarantee a similar outcome. This press release may be considered Attorney Advertising in some jurisdictions under applicable laws and ethical rules. Please see krcomplexlit.com for more details.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210629006104/en/
FAQ
What is the class action lawsuit against Athira Pharma about?
When was the Athira Pharma lawsuit filed?
What happened to Athira's stock price after the lawsuit was announced?
What is the legal basis for the Athira Pharma class action suit?
Can investors join the class action against Athira Pharma?
